X-ray Powder Diffraction Spectroscopy as a Robust Tool in Early Predicting Bioavailability of Pharmaceutical Formulation Containing Polymorphic Drug Substance

Author(s): Abhishesh K. Mehata*, Deepa Dehari, Senthil R. Ayyannan, Madaswamy S. Muthu

Journal Name: Drug Delivery Letters

Volume 10 , Issue 3 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


X-ray powder diffraction (XRPD) is a unique, solid-state analytical tool used to study the 3D structure of small or macromolecules by their x-ray diffraction or scattering patterns. X-ray diffraction by a crystal reflects the periodicity of crystal architecture; any imperfections within the crystal architecture can be easily identified by its poor diffraction pattern. Recently, an open crystallography database reported that more than 85 % of drug compounds are crystalline and exist in different polymorphic states. Physicochemical properties of pharmaceutical drug products composed of active pharmaceutical ingredients (APIs) and excipients are interdependent on the physical state and forms in which APIs are distributed in excipients that determine the in-vivo and ex-vivo performance of the product. Amorphous APIs have relatively higher dissolution and bioavailability than crystalline form but with lower phase stability. During the formulation development and storage phase, the conversion is higher that largely impacts the bioavailability of the drug product. In this manuscript, we have presented the case study of itraconazole and apigenin; both are crystalline APIs, that, with the help of solid dispersion technology, are converted into amorphous drug products with enhanced oral bioavailability. The realtime monitoring of the physical form of API in the formulation was possible with the help of XRPD and other supporting data obtained from differential scanning calorimeter (DSC), which can be correlated with the dissolution and in-vivo performance of the formulation.

Keywords: Amorphous, bioavailability, dissolution, solid dispersion, polymorphism, X-ray powder diffraction.

Srodon, J. X-ray powder diffraction identification of illitic materials. Clays Clay Miner., 1984, 32(5), 337-349.
Karjalainen, M.; Airaksinen, S.; Rantanen, J.; Aaltonen, J.; Yliruusi, J. Characterization of polymorphic solid-state changes using variable temperature X-ray powder diffraction. J. Pharm. Biomed. Anal., 2005, 39(1-2), 27-32.
[http://dx.doi.org/10.1016/j.jpba.2005.02.036] [PMID: 16085131]
Sharma, R.; Bisen, D.P.; Shukla, U.; Sharma, B.G. X-ray diffraction: a powerful method of characterizing nanomaterials. R. Res. Science Tech., 2012, 4(8), 77-79.
Annen, M.J.; Young, D.; Davis, M.E.; Cavin, O.B.; Hubbard, C.R. Thermal and hydrothermal stability of molecular sieve VPI-5 by in situ X-ray powder diffraction. J. Phys. Chem., 1991, 95(3), 1380-1383.
Platteau, C.; Lefebvre, J.; Affouard, F.; Willart, J.F.; Derollez, P.; Mallet, F. Structure determination of the stable anhydrous phase of α-lactose from X-ray powder diffraction. Acta Crystallogr. B, 2005, 61(Pt 2), 185-191.
[http://dx.doi.org/10.1107/S0108768105000455] [PMID: 15772451]
Litteer, B.; Beckers, D. Increasing application of X-ray powder diffraction in the pharmaceutical sindustry. Am. Lab., 2005, 37(12), 22-29.
Chauhan, A.; Chauhan, P. Powder XRD technique and its applications in science and technology. J. Anal. Bioanal. Tech., 2014, 5(5), 1-5.
Jung, J.Y.; Yoo, S.D.; Lee, S.H.; Kim, K.H.; Yoon, D.S.; Lee, K.H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm., 1999, 187(2), 209-218.
[http://dx.doi.org/10.1016/S0378-5173(99)00191-X] [PMID: 10502627]
DiNunzio, J.C.; Brough, C.; Miller, D.A.; Williams, R.O., III; McGinity, J.W. Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions. Eur. J. Pharm. Sci., 2010, 40(3), 179-187.
[http://dx.doi.org/10.1016/j.ejps.2010.03.002] [PMID: 20230894]
Hughey, J.R.; Keen, J.M.; Brough, C.; Saeger, S.; McGinity, J.W. Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol® Dispersing. Int. J. Pharm., 2011, 419(1-2), 222-230.
[http://dx.doi.org/10.1016/j.ijpharm.2011.08.007] [PMID: 21864663]
DiNunzio, J.C.; Brough, C.; Miller, D.A.; Williams, R.O., III; McGinity, J.W. Fusion processing of itraconazole solid dispersions by kinetisol dispersing: a comparative study to hot melt extrusion. J. Pharm. Sci., 2010, 99(3), 1239-1253.
[http://dx.doi.org/10.1002/jps.21893] [PMID: 19681106]
Kashyap, D.; Sharma, A.; Tuli, H.S.; Sak, K.; Garg, V.K.; Buttar, H.S.; Setzer, W.N.; Sethi, G. Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function. J. Funct. Foods, 2018, 48, 457-471.
Alshehri, S.M.; Shakeel, F.; Ibrahim, M.A.; Elzayat, E.M.; Altamimi, M.; Mohsin, K.; Almeanazel, O.T.; Alkholief, M.; Alshetaili, A.; Alsulays, B.; Alanazi, F.K.; Alsarra, I.A. Dissolution and bioavailability improvement of bioactive apigenin using solid dispersions prepared by different techniques. Saudi Pharm. J., 2019, 27(2), 264-273.
[http://dx.doi.org/10.1016/j.jsps.2018.11.008] [PMID: 30766439]

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 10 September, 2020
Page: [250 - 254]
Pages: 5
DOI: 10.2174/2210303110999200519074306
Price: $25

Article Metrics

PDF: 38
PRC: 2